Cure My Disease

Don't miss your cure!

 Log in / Sign up

Underactive thyroid may worsen liver scarring in fatty liver disease

NCT ID NCT07827430

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers at Assiut University are studying whether an underactive thyroid makes liver scarring worse in people with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial enrolls 120 adults with MASLD, half of whom have overt or subclinical hypothyroidism and half with normal thyroid function. All participants receive ultrasound, FibroScan, and blood tests to measure liver stiffness and fibrosis scores. Comparing the two groups could clarify whether thyroid deficiency independently contributes to advanced liver scarring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If thyroid deficiency turns out to worsen liver scarring, doctors could screen MASLD patients for hypothyroidism and treat it to slow liver damage.
What could go wrong
This observational study can show a link but not prove cause and effect. The 120 participants come from one Egyptian hospital, so results may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged \> 18 years diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) who attend the outpatient hepatology and endocrinology clinics at Assiut University Hospital, Assiut, Egypt. The population includes MASLD patients with newly diagnosed or pre-existing overt or subclinical hypothyroidism, as well as euthyroid MASLD patients.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged \> 18 years. * Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), defined as hepatic steatosis on abdominal ultrasound in the presence of at least one cardiometabolic risk factor (e.g., overweight/obesity, type 2 diabetes, or hypertension). * Newly diagnosed or pre-existing overt or subclinical hypothyroidism (for cases) or documented euthyroid status (for controls). * Availability of complete clinical and laboratory data required to calculate non-invasive liver fibrosis scores (FIB-4 index and NAFLD Fibrosis Score). * Provision of written informed consent to participate in the study. Exclusion Criteria: * Hyperthyroidism, history of thyroidectomy, or prior radioactive iodine therapy. * Chronic viral hepatitis (hepatitis B virus or hepatitis C virus). * Other secondary or specific chronic liver diseases (autoimmune hepatitis, primary biliary cholangitis, Wilson's disease, or hemochromatosis). * Decompensated liver cirrhosis or established hepatocellular carcinoma (HCC). * Significant alcohol consumption (to exclude alcohol-related liver disease). * End-stage renal disease (ESRD). * Congestive heart failure. * Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypothyroidism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fatty liver disease fibrotic liver disease hypothyroidism metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypothyroidism Liver fibrosis Metabolic dysfunction-associated steatotic liver disease Non-alcoholic fatty liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.